The components of other charges, net were as follows (in millions):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
Information technology transformation costs	$	2.2	$	2.2	$	4.9	$	3.3
Professional fees incurred in connection with investigations and other legal matters		9.0		0.2		10.5		0.5
Restructuring charges		3.1		3.7		7.8		4.3
Acquisition-related expenses, net		6.8		1.6		28.4		7.4
Other		1.6		1.7		5.0		4.6
Other charges, net	$	22.7	$	9.4	$	56.6	$	20.1

The following table sets forth the restructuring charges (in millions):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
Cost of revenues	$	1.2	$	1.1	$	9.8	$	1.4
Other charges, net	$	3.1		3.7		7.8		4.3
Total	$	4.3	$	4.8	$	17.6	$	5.7

The following table sets forth the changes in restructuring reserves (in millions):


	Total			Severance			Exit Costs			Provisions for Excess Inventory
Balance at December 31, 2023	$	13.1		$	9.6		$	2.9		$	0.6
Restructuring charges		17.6			7.6			4.5			5.5
Cash payments		(19.6	)		(14.7	)		(4.9	)		—
Other, non-cash adjustments and foreign currency effect		(5.6	)		(0.1	)		—			(5.5	)
Balance at September 30, 2024	$	5.5		$	2.4		$	2.5		$	0.6

In October 2023, the Company announced a restructuring plan associated with Bruker Cellular Analysis or “BCA” (formerly PhenomeX), a component of the NANO reportable segment, to optimize costs and to facilitate integration efforts. The restructuring plan includes a reduction in headcount, consolidation of leased facilities, and a planned change in future product offerings. The restructuring plan is expected to be completed during 2025.

In connection with the BCA restructuring plan, the Company recorded and accrued severance and termination charges of $1.3 million and $7.8 million in the three and nine months ended September 30, 2024, respectively. The Company made payments of $2.8 and $13.5 million in the three and nine months ended September 30, 2024, respectively. The remaining balance of accrued severance at September 30, 2024 is expected to be paid during the first half of 2025. As it relates to the consolidation of leased BCA facilities, the Company recorded an impairment charge against operating lease right of use assets of $1.5 million in the nine months ended September 30, 2024, with no additional impairment charge in the three months ended September 30, 2024. As of September 30, 2024, the Company does not expect any material impairment or termination charges in connection with the expected modification or termination of active operating leases. Due to delays in consolidating facilities, certain inventories that are expiring or have expired will no longer be usable for the manufacture of products. The cost of scrapped inventories of $4.7 million for the three and nine months ended September 30, 2024 was charged to product restructuring costs.

In April 2024, the Company announced a global restructuring program to reduce personnel costs affecting the BBIO, NANO and CALID Segments. The restructuring plan is expected to be completed during the first half of 2025. The Company recorded and accrued severance and termination charges of $2.3 million and $3.1 million in the three and nine months ended September 30, 2024, respectively. The Company made payments of $1.7 million and $2.8 million in the three and nine months ended September 30, 2024, respectively. The remaining balance of accrued severance at September 30, 2024 is expected to be paid during the first half of 2025. In connection with this restructuring plan, the Company closed one of its R&D facilities and recorded an impairment charge of $0.4 million for one of its technology intangible assets for the nine months ended September 30, 2024, with no additional impairment charge in the three months ended September 30, 2024.

Other restructuring programs relating to reductions in workforce recorded by the BSI NANO, BSI BioSpin, BSI CALID and Corporate segments in 2024 and 2023 were not material.